Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia

P. Charbel Issa, R. P. Finger, F. G. Holz, H. P.N. Scholl

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia'. Together they form a unique fingerprint.

Medicine & Life Sciences